{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:07:31Z","timestamp":1791198451693,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1525,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1002\/art.30372","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T17:09:32Z","timestamp":1301504972000},"page":"1782-1792","source":"Crossref","is-referenced-by-count":148,"title":["Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial"],"prefix":"10.1002","volume":"63","author":[{"given":"R. F.","family":"van Vollenhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kinnman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bathon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,6,29]]},"reference":[{"key":"10.1002\/art.30372-BIB1|cit1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","article-title":"Rheumatoid arthritis","volume":"373","author":"Klareskog","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/art.30372-BIB2|cit2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11926-007-0063-5","article-title":"Antibodies to citrullinated proteins: pathogenic and diagnostic significance","volume":"9","author":"Holers","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1002\/art.30372-BIB3|cit3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF02686079","article-title":"Auto-antibodies and autoreactive T-cells in rheumatoid arthritis: pathogenetic players and diagnostic tools","volume":"32","author":"Steiner","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1002\/art.30372-BIB4|cit4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/14712590903033919","article-title":"Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis","volume":"9","author":"Bracewell","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1002\/art.30372-BIB5|cit5","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB6|cit6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/art.23178","article-title":"Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study","volume":"58","author":"Tak","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB7|cit7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00228-007-0311-7","article-title":"Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers","volume":"63","author":"Munafo","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/art.30372-BIB8|cit8","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial","volume":"56","author":"Dall'Era","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB9|cit9","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.4049\/jimmunol.169.8.4314","article-title":"BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases","volume":"169","author":"Roschke","year":"2002","journal-title":"J Immunol"},{"key":"10.1002\/art.30372-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","article-title":"Elevated serum B lymphocyte stimulator levels in patients with systemic immune- based rheumatic diseases","volume":"44","author":"Cheema","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB11|cit11","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/art.10860","article-title":"Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis","volume":"48","author":"Tan","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB12|cit12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.coi.2007.04.008","article-title":"B cells and the BAFF\/APRIL axis: fast-forward on autoimmunity and signaling","volume":"19","author":"Mackay","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1002\/art.30372-BIB13|cit13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1196\/annals.1313.004","article-title":"BAFF overexpression is associated with autoantibody production in autoimmune diseases","volume":"1050","author":"Pers","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl","key":"10.1002\/art.30372-BIB14|cit14","first-page":"S444","article-title":"Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), selectively modulates B cell subpopulations and immunoglobulins in a heterogeneous rheumatoid arthritis population","volume":"52","author":"Stohl","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB15|cit15","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.4049\/jimmunol.180.6.3655","article-title":"Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL","volume":"180","author":"Benson","year":"2008","journal-title":"J Immunol"},{"key":"10.1002\/art.30372-BIB16|cit16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30372-BIB17|cit17","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1002\/art.22967","article-title":"Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment","volume":"56","author":"Teng","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/1078-0432.CCR-07-4435","article-title":"Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma","volume":"14","author":"Ansell","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1002\/art.30372-BIB19|cit19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jps.21839","article-title":"Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus","volume":"99","author":"Nestorov","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1002\/art.30372-BIB20|cit20","doi-asserted-by":"crossref","unstructured":"Genovese M Tak PP de La Bourdonnaye G Pena-Rossi C Kinnman N Efficacy and safety of atacicept in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor \u03b1 therapy: results of dose-finding AUGUST I trial 2010","DOI":"10.1002\/art.30373"},{"key":"10.1002\/art.30372-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/art.30373","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB22|cit22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB23|cit23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB24|cit24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB25|cit25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/ard.2010.130310","article-title":"The 2010 American College of Rheumatology\/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I","volume":"69","author":"Funovits","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"10.1002\/art.30372-BIB27|cit27","first-page":"S710","article-title":"Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population","volume":"52","author":"McKay","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB28|cit28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd1982","article-title":"An APRIL to remember: novel TNF ligands as therapeutic targets","volume":"5","author":"Dillon","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1002\/art.30372-BIB29|cit29","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1517\/14656566.7.18.2559","article-title":"Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis","volume":"7","author":"Dass","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1002\/art.30372-BIB30|cit30","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.4049\/jimmunol.162.5.3053","article-title":"Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis","volume":"162","author":"Kim","year":"1999","journal-title":"J Immunol"},{"key":"10.1002\/art.30372-BIB31|cit31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00428-002-0702-1","article-title":"Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis","volume":"441","author":"Magalhaes","year":"2002","journal-title":"Virchows Arch"},{"key":"10.1002\/art.30372-BIB32|cit32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/art.1780350108","article-title":"The B cell repertoire in rheumatoid arthritis. III. Preferential homing of rheumatoid factor-producing B cell precursors in the synovial fluid","volume":"35","author":"Moynier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB33|cit33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","article-title":"Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers","volume":"125","author":"Dorner","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1002\/art.30372-BIB34|cit34","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1172\/JCI25265","article-title":"BLyS and APRIL in rheumatoid arthritis","volume":"115","author":"Seyler","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1002\/art.30372-BIB35|cit35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/0091270008315312","article-title":"Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis","volume":"48","author":"Nestorov","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/art.30372-BIB36|cit36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.berh.2008.02.002","article-title":"Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials","volume":"22","author":"Gerlag","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1002\/art.30372-BIB37|cit37","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","article-title":"Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis","volume":"56","author":"Vos","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30372-BIB38|cit38","first-page":"656","article-title":"Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy","volume":"26","author":"Walsh","year":"2008","journal-title":"Clin Exp Rheumatol"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.30372","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/art.30372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T23:33:39Z","timestamp":1686008019000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.30372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,29]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"URL":"https:\/\/doi.org\/10.1002\/art.30372","relation":{},"ISSN":["0004-3591"],"issn-type":[{"value":"0004-3591","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6,29]]}}}